Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px
Document › Details

Axolabs GmbH. (11/28/11). "Press Release: Axolabs GmbH Completes Management Buy-out of Former Roche (RHHBY) Center of Excellence in Kulmbach". Kulmbach.

Region Region Kulmbach
  Country Germany
Organisations Organisation Axolabs GmbH
  Group LGC (Group)
  Organisation 2 Roche Kulmbach GmbH
  Today Axolabs GmbH
  Group LGC (Group)
Products Product siRNA technology
  Product 2 RNAi drug (RNAi therapeutic)
Index term Index term Roche–Axolabs: investment, 201111 management buy-out of former Roche Kulmbach operations to start as Axolabs GmbH
Persons Person Kreutzer, Roland (Roche Kulmbach 2007– Managing Director before Alnylam Europe 200602 Managing Director)
  Person 2 Bossko, Andreas (Axolabs 201603 Managing Director (CFO) before Roche Kulmbach + Ribopharma)
     


Axolabs GmbH, a custom research organization built on Roche Kulmbach GmbH, formerly Roche's Center of Excellence for RNA Therapeutics, has been acquired by its management from Roche Beteiligungs GmbH.

With a team of key scientists and technical personnel having world-leading know-how and 10+ years of experience in the nucleic acids therapeutics field, Axolabs provide high end research services ranging from nucleic acid drug discovery through preclinical R&D to clients and partners from the pharmaceutical, biotechnological and medical technology industry, clinical units, research facilities and also venture capital firms operating in the nucleic acids therapeutics field.

"After Roche had decided in November 2010 to discontinue the siRNA field scientifically and operationally we are glad to now be able to preserve a number of highly qualified positions at our former site in Kulmbach, Germany, by facilitating this buy-out of the Roche Kulmbach GmbH by the former management", says Hagen Pfundner, CEO Roche Pharma AG, Germany.

"We highly appreciate Roche's decision to support this MBO. This allows us to re-hire key employees necessary to cover all aspects of our services", says Andreas Bossko, Head of Finance and Administration, Axolabs GmbH.

"This step enables us to retain our world-leading know-how in the nucleic acid therapeutics field together with a fully equipped and operational site", says Dr. Roland Kreutzer, who originally co- founded the company under the name of Ribopharma AG in 2000 as the first company focusing on RNAi therapeutics.

Dr. Hans-Peter Vornlocher, Head of Research at Axolabs, comments: "With this organization we provide our outstanding expertise to our customers by offering a broad array of preclinical research services around nucleic acid therapeutics. The high interest in such research services as well as the excellent reputation of the Kulmbach team is reflected by the significant number of requests that we already received from the Pharma and Biotech industry."

Axolabs will have the custom research business fully operational by the end of this year and also plan to dedicate resources to internal research projects.

Please visit our website for further information: www.axolabs.com

Contact:

Axolabs GmbH
Dr. Roland Kreutzer
Fritz-Hornschuch-Str. 9
95326 Kulmbach
Germany

   
Record changed: 2017-04-02

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for LGC (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px




» top